Abstract 39P
Background
FOXC1, MKI67 and PDL1 expression that tracks plasticity, proliferation and immune evasion accurately predicts efficacy of Immune Checkpoint Blockade (ICB) with PD1/PDL1 inhibitor drugs. We sought to validate whether patient selection based on predicted Hyperprogressive Disease (HPD) risk using such an approach can improve Progression-free Survival (PFS) and/or Overall Survival (OS) in clinical trial and real world cohorts.
Methods
Pre-treatment tumor RNA-Seq data obtained from patients diagnosed with advanced/metastatic (a/m) melanoma (n=154,121), non-small cell lung cancer (NSCLC, n=82,140) and renal cell carcinoma (RCC, n=250,120) were analyzed for FOXC1, MKI67 and PDL1 expression, and correlated with overall response rate (ORR), PFS, OS and HPD, the latter defined as time-to-treatment-failure (TTF) <=2 months post-treatment initiation. Optimized biomarker cutoff values based on model AUC were leave-one-out cross validated and cancer-type specific (CTS) prediction algorithms derived. The unmodified strategy was then validated in the independent, CTS validation datasets.
Results
Predicted Clinical Responders (CR) displayed marked improvement in PFS and OS compared to Predicted Non-Responders with standard Progressive Disease (PD) or Hyperprogressive Disease (HPD). [a/m Melanoma OS HR=0.35 (0.187-0.666)95%CI, p=0.0004; a/m NSCLC OS HR=0.24 (0.119-0.499)95%CI, p<0.0001; a/m RCC OS HR= 0.45 (0.255-0.810)95%CI, p=0.008]. Table: 39P
Patient stratification by HPD risk and median overall survival benefit
Cancer type | Sample size | ICB median OS | HPD median OS | PD median OS | CR median OS |
Melanoma Liu et al | 121 | 22.5 mos | 5 mos | 17 mos | 37.5 mos |
NSCLC SU2C-mark cohort Ravi et al | 140 | 17 mos | 13 mos | 19 mos | 35.5 mos |
RCC CM-025 cohort Motzer et al | 120 | 27.5 mos | 17.5 mos | 22.5 mos | 57 mos |
Conclusions
Compared to ICB administered in a non-patient stratified manner, restricting ICB treatment only to those patients who are predicted CRs results in nearly a two-fold or greater improvement in the median OS survival benefit in all cancer types examined. Patients predicted to have elevated HPD risk should be considered for treatment with non-ICB regimens or offered enrollment in clinical trials that combine ICB with other drugs.
Clinical trial identification
NCT01668784; Nov 5, 2015.
Legal entity responsible for the study
P.S. Ray.
Funding
Has not received any funding.
Disclosure
P.S. Ray: Non-Financial Interests, Institutional, Advisory Role: Onconostic Technologies: Practicing surgical oncologist and clinical investigator, identified as the presenting author on the submitted abstract. PSR is not an employee of the company (Onconostic Tehcnologies), but is founder and Chairman of the Scientific Advisory Board of the company which is an unpaid position. T. Ray, R. Hussa: Financial Interests, Personal, Full or part-time Employment: Onconostic Technologies, Inc.; Financial Interests, Personal, Stocks/Shares: Onconostic Technologies, Inc. C. Taylor: Financial Interests, Personal, Advisory Board: Onconostic Technologies, Inc.; Financial Interests, Personal, Stocks/Shares: Onconostic Technologies, Inc.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display